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on naïve and exposed populations was available for colistin and colistin-P, respec-
tively. ConClusions: By conducting an alternative approach where the naïve and 
exposed arms were considered separate treatment-by-population groups, the full 
evidence base could be evaluated, including the data for the dry-powder colis-
timethate sodium inhaler. This will provide relevant information to support clinical 
decision making in CF.
PND8
CliNiCal EffECtivENEss of laCosamiDE aND its imPaCt oN 
CoNComitaNt aNtiEPilEPtiC Drugs CoNsumPtioN iN thE CzECh 
rEPubliC
Klimes J.1, Vocelka M.1, Dolezal T.1, Foitova H.2
1VALUE OUTCOMES, s.r.o., Prague 2, Czech Republic, 2UCB, s.r.o., Prague 8, Czech Republic
objeCtives: To gather data on clinical effectiveness of lacosamide add-on ther-
apy to standard antiepileptic drugs (AEDs) in the Czech Republic. These data were 
intended as inputs for a cost-effectiveness analysis. Methods: A retrospective 
multicenter (n= 40) data collection of patients with epilepsy treated with lacosamide 
for 6 months in clinical practice was performed. Information on the number of sei-
zures and concomitant AEDs before and after lacosamide treatment was observed. 
In this analysis patients reporting at least a 50% reduction in seizure number 3 
months after lacosamide treatment were considered responders. Adverse events 
reported after initiating lacosamide treatment were collected. Results: In total, 
data from 409 patients were collected, 403 had complete data that were analyzed. 
Mean (SD) age was 40.4 (±14.2) years and the mean (SD) time since diagnosis 18.7 
(±12.8) years. In 91% of patients lacosamide treatment was initiated because of 
resistance to previous AEDs. Most patients suffered from partial (44.2%), second-
ary generalized (20.1%) or both (34.0%) types of seizures, or other (1.7%). Following 
lacosamide administration the mean (median) number of seizures decreased from 
baseline of 40.3 (12.0) to 25.9 (7.0) (per 3 months). Median (mean) number of sei-
zure reduction was equal to 41% (30%), and 45% were responders. Adverse events 
occurred in 79 pts (19.6%), with somnolence (6.2%) and dizziness (5.5%) most fre-
quently reported. During lacosamide administration, a decrease in concomitant 
AEDs number was observed. The mean number per patient decreased from 2.2 to 
1.7, as did concomitant AEDs used before and after lacosamide administration: 
levetiracetam (39% vs. 33%), lamotrigine (38% vs. 32%), carbamazepine (34% vs. 
29%), valproate (33% vs. 28%) and zonisamide (17% vs. 8%). ConClusions: Results 
confirm the effectiveness of lacosamide in the reduction of seizure frequency in 
clinical practice. In addition, findings suggest that adding lacosamide may lead to 
a reduced use of other concomitant AEDs.
PND9
Cost aNalysis of aNti-migraiNE PrEsCribiNg usiNg a Claims DatabasE
Truter I.
Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
objeCtives: To analyse the cost of different anti-migraine products to determine 
price differences and the impact of generic prescribing. Methods: A retrospective 
drug utilisation study was conducted on South African medical insurance claims 
data for 2011. No clinical information was available. Results: A total of 797 patients 
received 1583 anti-migraine products during 2011. The majority of patients (70.14%) 
were females and 47.05% of patients were between 30 and 49 years old. Only 13.96% 
of patients claimed their anti-migraine products from the chronic plan of their 
medical insurance schemes. The average age of patients was 41.61 (SD= 14.91) years, 
with females on average slightly older than males (41.89 years vs. 40.96 years). 
Clonidine was the most frequently prescribed active ingredient (accounting for 
49.21% of the number of prescriptions, yet only for 25.70% of the amount claimed for 
anti-migraine products). Triptans (selective serotonin (5-HT1B/1D)-receptor agonists) 
accounted for 27.98% of all anti-migraine prescriptions, but accounted for 45.92% 
of cost. Five different triptans were prescribed. The average cost per sumatriptan 
prescription was the lowest (R177.64) of all the triptans. Sumatriptan was the only 
triptan with generic equivalents. Rizatriptan was the most often prescribed triptan, 
accounting for 18.51% of prescribing frequency and 29.15% of the amount claimed. 
Tablets and wafers were the preferred dosage forms. Only 0.32% of prescriptions 
were for triptan nasal sprays and they were on average the most expensive dos-
age form prescribed (R428.82 per prescription). ConClusions: The results of this 
study were in agreement with the findings of previous South African studies. The 
cost saving implications of generic prescribing were clear in this study. Migraine is 
an expensive condition to treat and is also affecting the economically active sec-
tor of the population. Studies investigating the economic impact of migraine will 
therefore yield valuable results.
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PraCtiCE of CErEbroProtECtors CoNsumPtioN iN ukraiNE
Kuznetsov I., Iakovlieva L., Ribka A., Vasileva A., Kyrychenko O.
National University of Pharmacy, Kharkiv, Ukraine
objeCtives: Despite the lack of evidence-based efficacy of cerebroprotective drugs, 
one-third of Europe’s population uses of these drugs (WHO statistics). The pur-
pose of the study - to research the dynamics of cerebroprotectors consumption in 
Ukraine. Methods: Determination of cerebroprotectors consumption by means of 
frequency analysis, ATC/DDD-methodology during 6 months in 2012 in Ukraine. The 
consumption of cerebroprotective drugs in money term does not give a true picture 
about the volume of pharmacotherapy using these drugs, that is why ATC/DDD-
methodology was used. As a unit of consumption DDD and PDD were used. Results: 
A comparison of outpatient and inpatient cerebroprotective drugs consumption 
during 6 months in a neurological hospital and in a drugstore in Kharkov, it was 
found, that 58 trade names (TN) of drugs in the amount of $ 28218 (the rate of $ 1: 
8,16 UAH on 1.10.12), in the hospital 17 TNs were used in the amount of $1518. It is 
shown, that the inpatient consumption of cerebroprotectors is much higher, than 
outpatient consumption, for example, vincamine - 2,32 DDDs/100 patients and 1,66 
DDDs/100 bed–days; piracetam - 2,59 DDDs /100 patients and 0, 15 DDDs/100 bed-
objeCtives: To assess the effects of early psychosocial intervention on delaying the 
institutionalization of patients with mild Alzheimer’s disease (AD) and on caregiv-
ers’ health-related quality of life (HRQOL). Methods: Totally, 240 patient-caregiver 
dyads were recruited to a pragmatic, controlled, and randomized (1:2) clinical trial 
in 3 hospital districts in Finland between 2002-2006. A primary outcome measure 
was the intervention’s impact on cumulative risk of institutionalization over 36 
months of follow up. In the analysis of the primary outcome, Fine & Gray’s (1999) 
proportional subhazards (sHR) model was applied to adjust the impact of compet-
ing risk (i.e., death). Main secondary outcome measures were caregivers’ global 
burden (measured by Global Health Questionnaire GHQ) and HRQOL measured by 
the 15D. The secondary outcomes were analyzed using generalized linear mixed 
models (GLMM) with hierarchical structure to account for repeated measures and 
possible clustering by the hospital district. Results: After 36 months of follow 
up, cumulative competing risk adjusted incidence of institutionalization rates 
(95% CI) were 21.2% (12.5% – 29.9%) and 16.1% (10.3% - 21.9%) in the intervention 
and usual care groups, respectively. Age and sex adjusted sHR was 1.37 (95%CI 
0.75 – 2.52). No statistical significant differences in the secondary outcomes were 
found. ConClusions: The early psychosocial intervention for patients with mild 
AD and their caregivers did not delay time to nursing home placement. The results 
of the present study are consistent with a recently published study (Waldorff et al. 
2012 BMJ) reporting no effect of semi-tailored intervention for patients with mild 
AD and their caregivers. Even if the present study did not manage to show differ-
ences between the study groups, it provides the valuable longitudinal dataset for 
studying long-term disease progression (in terms of correlated cognitive, behavioral, 
and functional disabilities) and its economic and quality of life consequences for 
patients with AD and their caregivers.
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moDEliNg thE imPaCt of DisEasE moDifyiNg trEatmENt oN timE to 
Disability hEalth statEs iN multiPlE sClErosis: aN EvaluatioN 
of oral thEraPiEs through iNDirECt ComParisoNs of 6-moNth 
CoNfirmED Disability ProgrEssioN
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objeCtives: To estimate the comparative efficacy of oral therapies (fingolimod, dime-
thyl fumarate [DMF] and teriflunomide) in delaying progression to disability health 
states in patients with relapsing–remitting multiple sclerosis (RRMS). Methods: Cox 
proportional hazards regression models were used to analyse 6-month confirmed 
disability progression (CDP; based on Expanded Disability Status Scale [EDSS] scores) 
in the pooled fingolimod FREEDOMS trials. Initial models were constructed with eight 
baseline covariates as main and treatment-interaction effects and final models with 
the most predictive covariates were selected using a stepwise algorithm. Models 
predicted hazard ratios (HRs) for 6-month CDP for fingolimod 0.5mg versus placebo 
for average TEMSO (teriflunomide trial) and pooled DEFINE/CONFIRM (DMF trials) 
patients. Time from EDSS score 0 to scores of 4 or 6 and to conversion to secondary 
progressive multiple sclerosis (SPMS) were estimated by fitting a multi-state Markov 
Transition model to individual patient data from the pooled FREEDOMS placebo 
groups (HRs accounted for treatment effects) and the London Ontario cohort (SPMS 
and RRMS–SPMS transitions). Results: Without covariate adjustment, the HR for 
CDP for fingolimod versus placebo in the pooled FREEDOMS trials was numerically 
lower (i.e. fingolimod more efficacious) than that for DMF twice daily versus placebo 
in DEFINE/CONFIRM (0.62 vs. 0.71). In adjusted comparisons, the predicted HR for 
fingolimod versus placebo in the DEFINE/CONFIRM population was lower than in the 
FREEDOMS population (initial model, 0.51; final model, 0.60). Fingolimod increased 
median time to disability health states (EDSS 4, 1.0 years; EDSS 6, 1.5 years) and SPMS 
(1.9 years) compared with DMF. Comparisons with teriflunomide also showed fingoli-
mod increased times to disability health states. ConClusions: Fingolimod is the 
only oral treatment that has demonstrated a significant effect on 6-month CDP in a 
clinical trial and our modeling approach suggests that progression to severe disability 
health states is delayed by fingolimod.
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objeCtives: To compare the efficacy of tobramycin powder for inhalation (TIP) rela-
tive to tobramycin inhalation solution containing 300 mg/5ml of tobramycin (TIS-T) 
and 300mg/4ml of tobramycin (TIS-B), aztreonam lysine inhalation solution (AZLI), 
colistimethate sodium solution (colistin) and colistin inhalation powder (colistin-
P) for cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosainfection, 
by updating a systematic literature review (SLR) and network meta-analysis (NMA) 
with recently published evidence. Methods: The updated SLR was conducted in 
Medline, Medline in Process, Embase and the Cochrane Library up to 2012. Individual 
study results were synthesized and indirectly compared with a Bayesian NMA. As 
some trials included naïve patients (previously not exposed to the treatment) in one 
arm, and previously exposed patients to the treatment in the other arm, the naïve 
and exposed arms were considered separate treatment-by-population groups in 
the network. Results: Three new trials were identified and analysed with eleven 
trials identified in the previous SLR. In naïve populations, TIP is expected to have 
similar efficacy as TIS-T, TIS-B, and AZLI (difference in % change in FEV1 predicted 
at week 4 respectively -1.97 (95% Credible Interval -11.84, 8.03), -2.38 (-12.71, 7.98), 
and 1.53 (-7.04, 10.00)). Compared to colistin-P, TIP is expected to have similar effi-
cacy, however the point estimate is in favour of TIP (11.36 (-1.75, 24.31)). In exposed 
populations, TIP is expected to have similar efficacy as TIS-T, TIS-B and colistin 
(respectively -0.78 (-7.65, 5.99), 0.01 (-10.42, 10.46), and -5.75 (-21.23, 9.89)). No data 
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or best supportive care (BSC). Methods: The BIM was developed from the UK 
NHS (National Health Service) and Personal and Social Services (PSS) perspective. 
The status quo scenario assumed the three BoNT-As, Dysport® (abobotulinum-
toxinA), Botox® (onabotulinumtoxinA), or Xeomin® (incobotulinumtoxinA), are 
used in 33%, 52% and 15%, respectively, of patients with ULS receiving BoNT-A 
in the UK. The new market share scenario assumed an increased proportional 
use of abobotulinumtoxinA (to 73% in year 5) compared to other interventions. 
The patients were modelled over a 5-year horizon. Epidemiologic data inputs 
were from published sources. Unit costs for BoNT-As, other health care costs and 
non-medical costs came from the British National Formularyand PSS. Resource-use 
inputs were obtained from UK clinicians. One-way sensitivity analyses for model 
inputs were conducted. Results: Total care costs were decreased by between 
£425,765 in year 2 and £1,854,601 in year 5 by shifting market share to abobo-
tulinumtoxinA. In the base-case scenario, BSC (no BoNT-A treatment) or with 
incobotulinumtoxinA or onabotulinumtoxinA cost more per patient per year than 
abobotulinumtoxinA. Sensitivity analyses showed that number of patients treated 
with BoNT-As, time-to-re-injection, and dose per injection of abobotulinumtoxinA 
and onabotulinumtoxinA were the most influential parameters on budget impact, 
impacting both drug acquisition costs and physician visits. ConClusions: Study 
findings suggest that increased use of abobotulinumtoxinA compared with inco-
botulinumtoxinA and onabotulinumtoxinA for ULS in the UK could potentially 
reduce total treatment costs.
PND14
thE buDgEt imPaCt of iNtroDuCiNg bg-12 (DimEthyl fumaratE) for 
trEatmENt of rElaPsE-rEmittiNg multiPlE sClErosis (rrms) iN CaNaDa
Dorman E.1, Kansal A.R.1, Sarda S.2
1Evidera, Bethesda, MD, USA, 2Biogen Idec, Weston, MA, USA
objeCtives: Multiple sclerosis causes significant disability and mortality globally 
and is especially prevalent in Canada and across Europe. BG-12 is an orally admin-
istered disease modifying treatment for relapsing-remitting MS (RRMS) patients 
currently on the market in the United States and Canada and under review in 
Europe. A budget impact model (BIM) was developed to assess the financial con-
sequences of introducing BG-12 for the treatment of RRMS in Canada. Methods: 
A BIM calculated the financial consequences of introducing BG-12 in Canada over 
three years based on RRMS prevalence, treatment market share, and clinical effects. 
RRMS prevalence in Canada was derived from published literature and natural 
relapse rates and disease state distribution from clinical trial data. It was conserva-
tively assumed that 100% of RRMS patients were treated with a disease modifying 
treatment. BG-12 was assumed to absorb market share proportionally from the 
following current treatments: interferon beta-1a IM, interferon beta-1a SC, inter-
feron beta-1b, glatiramer acetate, natalizumab, and fingolimod. Treatment efficacy, 
in terms of reductions in relapse rate, and treatment discontinuation rates were 
determined from a mixed treatment comparison. Treatment costs (including costs 
of acquisition, monitoring, and administration) and the cost of relapse were con-
sidered. Deterministic one-way sensitivity analyses were conducted to assess the 
most sensitive input parameters. Results: Over three years, the introduction of 
BG-12 resulted in an average annual increase of CAD279 per treated patient per year, 
with reductions in costs associated with relapses (CAD192/patient/year) partially 
offsetting increased drug acquisition costs (CAD471/patient/year). On a popula-
tion level, the average annual cost increase was CAD16,494,850. The main drivers 
of budget impact were cost of BG-12, drop-out rates, proportion of RRMS patients 
treated, and market share assumptions. ConClusions: The acquisition costs of 
BG-12 for treatment of RRMS are predicted to be partially offset by reduced costs of 
relapses in the Canadian health care system.
PND15
buDgEt imPaCt of EvErolimus for tubErous sClErosis ComPlEx (tsC) 
rElatED aNgiomyoliPoma (aml): uNitED kiNgDom PErsPECtivE
Whalen J.D.1, Srivastava B.2, Ozer-Stillman I.1, Gray L.3, Price L.3, Magestro M.2
1Evidera, Lexington, MA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 
3Novartis Pharmaceuticals UK Limited, Frimley, UK
objeCtives: AMLs are benign tumors common in patients with TSC, associated 
with high morbidity (aneurysm, hemorrhage, chronic kidney disease), and can 
result in death. Complication risk may correlate with increased AML volume. 
Historically, AMLs were treated surgically with embolization or tissue-sparing 
resection. In the EXIST-2 trial, everolimus significantly reduced AML volume in 
TSC patients. This analysis estimates the cost of reimbursing everolimus for TSC-
related AML to the UK health care system. Methods: A Markov model was built to 
analyze budget impact over five years. The treated population is estimated using 
TSC and AML prevalence. Adult patients with growing AML ≥ 3 cm are assumed 
eligible for everolimus. Treatment reference costs are from the UK, resource utili-
zation data from The Netherlands, efficacy and safety assumptions from EXIST-2. 
The model assumed one-year treatment duration. Responding patients (≥ 30% 
AML volume reduction) may restart everolimus upon AML regrowth. Costs are 
discounted at 3.5% per annum. Sensitivity analyses were conducted. Results: 
Up to 1,474 adults in the UK have TSC-related AML; 30% are assumed eligible 
for everolimus. On average, 165 patients are estimated to be treated annually 
with everolimus (Year 1: 88; Year 5: 233) at an average cost of £4,600,000 (Year 
1: £2,700,000; Year 5: £6,200,000). Over five years, AML-related medical spending 
decreased £54,000. Annual per patient treatment cost with everolimus is £31,000. 
Results were most sensitive to patient prevalence, percent eligible for everolimus, 
and the percent experiencing ≥ 30% AML volume reduction. ConClusions: TSC 
is a relatively rare genetic disease for which everolimus is the only non-surgical 
treatment that has demonstrated efficacy in reducing AML volume. Reducing AML 
volume may prevent long-term complications and avoid surgeries, resulting in 
decreased AML-related medical costs. Further long-term studies are needed to 
better understand the benefits of everolimus in preventing AML-related morbidity 
and the associated costs.
days, respectively. By frequency of outpatient appointments a combined generic drug 
fezam (234 appointments, prise $ 5.1), and outpatient cavinton (19 appointments, 
prise $ 17.27) were used often. ConClusions: In Ukraine, outpatient cerebroprotec-
tive drugs consumption is greater than their consumption in hospital due to the lack 
of prescriptions control.
PND11
utilizatioN of aNti sPastiCity Drugs iN multiPlE sClErosis: aNalysis 
from aN italiaN aDmiNistrativE DatabasE
Mantovani L.G.1, Furneri G.2, Scalone L.3, Ciampichini R.2, Cortesi P.A.3, Fornari C.3,  
Madotto F.3, Chiodini V.3, Cesana G.3
1Federico II University of Naples, Naples, Italy, 2Charta Foundation, Milan, Italy, 3University of 
Milano - Bicocca, Monza, Italy
objeCtives: Spasticity is a common condition among patients with progres-
sive and/or relapsing forms of multiple sclerosis (MS). Current therapies seem to 
partially control spasticity symptoms, and patients often receive multiple treat-
ments or switch to new treatments to achieve a better control. The objective of 
this analysis was to assess the current usage of spasticity drugs and relative 
patterns of utilization among patients with MS, through administrative database 
analysis. Methods: Using DENALI datawarehouse, we detected MS patients 
who, during the period January 2000 – December 2009, had at least one disease 
modifying agent (DMA) prescription Then the usage of drugs commonly used 
in spasticity (muscle relaxant drugs, baclofen, tizanidine, clonidine, dantrolene) 
was evaluated in this cohort of patients, in terms of number of subjects receiving 
at least one prescription, and number of DDD (defined daily doses) per patient 
per year. Results: From 2000 to 2009, the annual number of patients with MS, 
receiving DMA treatment raised from 10,746 to 12,594. Concomitantly, the annual 
number of patients receiving at least one muscle relaxant prescription raised from 
5.87% (n= 631) to 9.42% (n= 1,186). The most prescribed drug was baclofen with few 
patients receiving other drugs commonly indicated in spasticity (dantrolene, tiza-
nidine and clonidine). A relevant number of patients using muscle relaxants also 
received other drugs for the central nervous system, although its usage achieved 
a peak in 2005 (8% of MS patients). The analysis of DDD per patient/year suggested 
that the usage of muscle relaxant might be almost chronic in these patients (in 
2009, 303 DDD per patients per year). ConClusions: Only 10% of patients with 
MS currently receive active pharmacological treatment, although this condition 
seems affecting more than 20% of MS patients in Europe. Also, there are not rel-
evant alternatives or second line options to baclofen, which is the most commonly 
prescribed drug in this condition.
PND12
usE of thE frENCh Claims aND hosPitalisatioNs DatabasE to EstimatE 
thE PrEvalENCE aND iNCiDENCE of ParkiNsoN’s DisEasE iN fraNCE
Blin P.1, Dureau C.1, Grolleau A.1, Corbillon E.2, Jové J.1, Lassalle R.1, Poutignat N.2,  
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objeCtives: Few studies have assessed the prevalence and incidence of Parkinson’s 
disease (PD) in France. The objectives of this study were to estimate the prevalence 
and incidence of PD between 2005 and 2010 using a claims and hospitalisations 
database. Methods: The EGB database is a 1/97 permanent random sample of 
the French health care insurance system database linked to the national hospital 
discharge summary database. Data for all adults with full insurance coverage for 
PD, or hospitalised with main, related, or associated PD diagnosis, or with at least 3 
antiparkinson agent reimbursements over a one-year period were extracted for the 
years 2004 to 2010. A specific and a sensitive PD criterion were defined: i) patients 
with a medical diagnosis of PD from full insurance coverage or hospitalisation; ii) 
same patients plus those without a PD medical diagnosis in the database but a 
drug pattern compatible with this diagnosis (a second set of at least 3 antiparkin-
son agent reimbursements over another one-year period and no co-medication 
with extrapyramidal side effects, as well as no antiparkinson agent pattern spe-
cific of another indication). EGB estimations were applied to the French population 
with age and gender standardization to estimate the prevalence and incidence in 
France. Results: Prevalence of PD increased from 0.27% in 2005 to 0.33% in 2010 
using the specific definition of disease, and from 0.38% to 0.46% using the sensitive 
definition. The incidence rate per year was 0.03-0.04% using the specific definition 
of disease, and 0.05-0.06% using the sensitive definition. Estimated population size 
was between 180,000 and 255,000 persons in 2010 with approximately 22,000 to 
32,000 new patients per year. ConClusions: The prevalence and incidence of PD 
in France are likely to be within the range of estimations found in the EGB database 
using the specific and sensitive definitions of disease; results are consistent with 
that reported internationally.
NEurologiCal DisorDErs – Cost studies
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buDgEt imPaCt aNalysis of botuliNum toxiN a thEraPy for uPPEr limb 
sPastiCity iN thE uNitED kiNgDom
Kurth H.1, Remak E.2, Hortobagyl L.3, Desai K.3, Abogunrin S.3, Dinet J.4, Gabriel S.4,  
Bakheit A.M.5
1IPSEN Pharma, Boulogne Billancourt, France, 2Evidera, Budapest, Hungary, 3Evidera, London, UK, 
4IPSEN Pharma, Boulogne-Billancourt, France, 5Moseley Hall Hospital, Birmingham, UK
objeCtives: Upper limb spasticity (ULS) secondary to upper motor neurone 
lesions has a considerable patient and caregiver burden, particularly with regards 
to pain, activities of daily living and personal care. BotulinumtoxinA (BoNT-A) 
injections are effective in treating ULS. We developed a budget impact model 
(BIM) to assess different BoNT-A treatments available in the UK for reducing 
ULS. We also assessed annual costs of treating each ULS patient with BoNT-A 
